Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc(NASDAQ:BBIO) has announced an exclusive license withBristol Myers Squibb Co(NYSE:BMY) to develop and commercialize BBP-398 in oncology.
BridgeBio will receive an upfront payment of $90 million, up to $815 million in milestone payments and tiered royalties in the low- to mid-teens.
BridgeBio will retain the option to acquire higher royalties in the U.S. in connection with funding a portion of development costs upon the...
Login or create a forever free account to read this news
Sign up/Log in